Clinical Trial Update: A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

View source ↗

Summary

A real-world study of alpelisib in combination with fulvestrant for HR-positive, HER2-negative, PIK3CA-mutant breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation | Status: TERMINATED